Table 3.

Prostate cancer risk loci associated with clinical variables at the time of prostate cancer diagnosis (P < 0.05)

Age at diagnosis
SNPLocationGenotypenMedian (q1, q3)P
rs7679673chr4:1062809830.0013
AA61062 (55, 68)
AC1,87361 (56, 68)
CC1,45560 (55, 66)
rs9364554chr6:1607536540.0004
CC2,01461 (56, 68)
CT1,58661 (55, 67)
TT32460 (54, 65)
rs13254738chr8:1281735250.0002
AA1,71260 (55, 67)
AC1,74462 (56, 68)
CC45861 (56, 67)
rs6983267chr8:1284824870.006
GG1,23760 (55, 67)
GT1,86361 (55, 67)
TT83162 (56, 68)
rs4430796chr17:331721530.0007
AA1,19560 (55, 66)
AG1,94361 (56, 67)
GG79662 (56, 68)
rs1859962chr17:666203480.017
GG1,06060 (55, 67)
GT2,03861 (55, 67)
TT83761 (56, 68)
rs2735839chr19:560564350.008
AA6664 (58, 68)
AG94362 (56, 67)
GG2,91861 (55, 67)
PSA at diagnosis, ng/mL
rs16901979chr8:1281940980.03
AA129.2 (6.2, 14.3)
AC3046.5 (4.9, 12.8)
CC3,2646.4 (4.6, 10.8)
rs1859962chr17:666203480.0037
GG9596.2 (4.6, 10.1)
GT1,8456.3 (4.6, 11.0)
TT7766.9 (4.9, 12.0)
Biopsy Gleason score
rs6983267chr8:1284824870.033
GG622389207
GT873614327
TT363274174
rs7000448chr8:1285103520.044
CC646465281
CT888622306
TT316185119
rs2735839chr19:560564350.00005
AA192224
AG396307203
GG1,443945481
Risk of aggressive disease
SNPLocationGenotypenMedian (q1, q3)P
rs445114chr8:1283923630.045
CC134159135
CT565627447
TT586566399
rs620861chr8:1284048550.016
AA130157134
AG551619445
GG605580405
rs7931342chr11:687510730.03
GG469453325
GT587648445
TT211220202
rs2735839chr19:560564350.0003
AA262611
AG267314281
GG9981,009693